Data Insights
By Company Name
No filters selected
By Disease Name
No filters selected
By Drug Name
No filters selected
By Themes
No filters selected
Showing 2 results out of 2
Data Insights
Risk adjusted net present value: What is the current valuation of Neurocrine Biosciences's Apinocaltamide?
Apinocaltamide is a small molecule commercialized by Neurocrine Biosciences, with a leading Phase II program in Epileptic Encephalopathy. According to...
Data Insights
Apinocaltamide by Neurocrine Biosciences for Epileptic Encephalopathy: Likelihood of Approval
Apinocaltamide is under clinical development by Neurocrine Biosciences and currently in Phase II for Epileptic Encephalopathy. According to GlobalData, Phase...